Study of the IgA Repertoire During IgA Deposition Nephropathy.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-15

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on the contrary, anti-inflammatory and inducing tolerance. Similarly, and for reasons that remain very poorly understood, they can be involved in pathologies where the immune system is itself an aggressor of the body and responsible for immunopathological lesions.

The investigator formulates the hypothesis that an inappropriate response of the mucosal immune system to one or more antigens leads to a synthesis of IgA of bad affinity favoring a deposit at the level of the mesangium. It seems important to verify this point by analyzing the IgA repertory of patients with N-IgA and comparing it to that of a control population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy

NCT05791162

Glomerulonephritis, IGA

RECRUITING NA

Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy

NCT00521508

Glomerulonephritis, IGA

COMPLETED NA

IgA Nephropathy, Lymphocyte Homing and IgA Class Switch

NCT01775527

IgA Nephropathy

COMPLETED NA

Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)

NCT07295808

Kidney Disease

RECRUITING NA

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

NCT06926244

IgA Nephropathy (IgAN)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be capable of triggering either a protective inflammatory response or, on the contrary, anti-inflammatory and inducing tolerance. Similarly, and for reasons that remain very poorly understood, they can be involved in pathologies where the immune system is itself an aggressor of the body and responsible for immunopathological lesions.

the investigator formulates the hypothesis that an inappropriate response of the mucosal immune system to one or more antigens leads to a synthesis of IgA of bad affinity favoring a deposit at the level of the mesangium. It seems important to verify this point by analyzing the IgA repertory of patients with N-IgA and comparing it to that of a control population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glomerulonephritis, IGA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 blood sample

1 blood sample during a consultation carried out as part of a medical follow-up:

* 2 PAXgene RNA tubes of 2 ml each
* 1 dry tube for creatinine and IgA assay
* 1 tube of NFs (5ml)

blood sample

Intervention Type OTHER

1 blood sample during a consultation carried out as part of a medical follow-up:

* 2 PAXgene RNA tubes of 2 ml each
* 1 dry tube for creatinine and IgA assay
* 1 tube of NFs (5ml)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

1 blood sample during a consultation carried out as part of a medical follow-up:

* 2 PAXgene RNA tubes of 2 ml each
* 1 dry tube for creatinine and IgA assay
* 1 tube of NFs (5ml)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Control population:

* person between the ages of 18 and 55 (persons matched to age and sex (75% male) (N-IgA is more common in humans) free from any pathology.

oAbsence of proteinuria and hematuria on urine sample (search by strip).

* Patients with N-IgA

* 40 patients with N-IgA whose diagnosis was confirmed by renal biopsy. These may be previously known patients who have not received treatment with corticosteroids or immunosuppressants for 12 months or new patients. The incidence of N-IgA is 20 patients per Mh; the number of incident patients with N-IgA is 10-15 per year in the nephrology department. The recruitment of 40 patients over 1 year is feasible.
* Participant's written consent

Exclusion Criteria

* Secondary or associated N-IgA (infection, malignant disease, inflammatory bowel disease,
* Rheumatic autoimmune disease or other;
* treatment with corticosteroids or immunosuppressants for less than 12 months.
* person on dialysis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes